PSNL Personalis

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on and .

EN
14/02/2024

Underlying

PSNLPersonalis

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Personalis

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.69
DHR DANAHER CORPORA...
ILMN ILLUMINA INC. ... (+17)

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

DHR DANAHER CORPORATION
ILMN ILLUMINA INC.
WAT WATERS CORPORATION
TECH BIO-TECHNE CORPORATION
PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BRKR BRUKER CORPORATION
A AGILENT TECHNOLOGIES INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
PKI PERKINELMER INC.
NTLA INTELLIA THERAPEUTICS INC.
CRSP CRISPR THERAPEUTICS AG
AVTR AVANTOR INC.
PSNL PERSONALIS
TWST TWIST BIOSCIENCE
PGEN PRECIGEN INC
OGEN ORAGENICS INC.
10/23/25 October 23, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
ACM AECOM
EME EMCOR GROUP
SGMO SANGAMO THERAPEUTICS INC.
PWR QUANTA SERVICES INC.
MTZ MASTEC INC.
EZPW EZCORP INC. CLASS A
ENVA ENOVA INTERNATIONAL INC
CRSP CRISPR THERAPEUTICS AG
XBI SPDR S&P BIOTECH ETF
PSNL PERSONALIS
FCFS FIRSTCASH HLDGS INC
MVST MICROVAST HLDGS INC
J JACOBS SOLUTIONS INC.
ARKG ARK GENOMIC REVOLUTION MULTI-SECTOR ETF
PRME PRIME MEDICINE INC
GRALV GRAIL INC.
ABAT AMERICAN BATTERY TECHNOLOGY COMPANY
ELA ENTERGY LA LLC DEB 5.875%41
09/30/25 September 30, 2025 1 EN
 PRESS RELEASE
Free
PSNL PERSONALIS

New Publication from ICR and Royal Marsden Researchers Highlights the ...

FREMONT, Calif.--(BUSINESS WIRE)-- (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in the UK, published results from their early-stage breast cancer study in Annals of Oncology. In this groundbreaking study, the authors highlight advancements in breast cancer residual disease (MRD) and recurrence detection using NeXT Personal®, an ultra-sensitive personalized test designed to detect small traces of circulating tumor DNA (ctDNA) in the blood of canc...

March 3, 2025 1 EN
 PRESS RELEASE
Free
PSNL PERSONALIS

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrenc...

FREMONT, Calif.--(BUSINESS WIRE)-- . (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine. In this groundbreaking study funded by Cancer Research UK, co-authors Black and Bartha et al. highlight advancements in lung cancer detection using NeXT Personal®, an ultra-sensitive personalized test designed to detect small traces of circulating tumor DNA (ctDNA) in the blood of cancer patients and survivors. In this study, NeXT...

January 13, 2025 1 EN
 PRESS RELEASE
Free
PSNL PERSONALIS

Personalis Advances Business Strategy with Investment from Merck and E...

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen therapy (INT), being jointly developed by Merck and Moderna. Merck has agreed to purchase $50 mill...

December 19, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch